Business

Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase III Clinical Trial of Polyethylene Glycol Irinotecan for Treatment of Small Cell Lung Cancer

Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase III Clinical Trial of Polyethylene Glycol Irinotecan for Treatment of Small Cell Lung Cancer

articleJenkem Technology Co., Ltd. Class ASeptember 29, 20244/news/announcement-on-voluntary-disclosure-of-the-first-subject-being-enrolled-in-phase-iii-clinical-trial-of-polyethylene-glycol-irinotecan-for-treatment-of-small-cell-lung-cancer
Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase III Clinical Trial of Polyethylene Glycol Irinotecan for Treatment of Small Cell Lung Cancer

About this update from Jenkem Technology Co., Ltd. Class A

Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase III Clinical Trial of Polyethylene Glycol Irinotecan for Treatment of Small Cell Lung CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jenkem Technology Co., Ltd. Class A